References
- Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021 May;71(3):209–249. DOI:https://doi.org/10.3322/caac.21660.
- Ferlay J, Partensky C, Bray F. More deaths from pancreatic cancer than breast cancer in the EU by 2017. Acta Oncol. 2016 Sep - Oct;55(9–10):1158–1160.
- Mizrahi JD, Surana R, Valle JW, et al. Pancreatic cancer. Lancet. 2020 Jun 27;395(10242):2008–2020.
- O’Reilly EM, Oh DY, Dhani N, et al. Durvalumab with or without tremelimumab for patients with metastatic pancreatic ductal adenocarcinoma: a Phase 2 randomized clinical trial. JAMA Oncol. 2019 Oct 1;5(10):1431–1438.
- Von Hoff DD, Ramanathan RK, Borad MJ, et al. Gemcitabine plus nab-paclitaxel is an active regimen in patients with advanced pancreatic cancer: a phase I/II trial. J Clin Oncol. 2011 Dec 1;29(34):4548–4554.
- Ramanathan RK, McDonough SL, Philip PA, et al. Phase IB/II randomized study of FOLFIRINOX plus pegylated recombinant human hyaluronidase versus FOLFIRINOX alone in patients with metastatic pancreatic adenocarcinoma: SWOG S1313. J Clin Oncol. 2019 May 1;37(13):1062–1069.
- Bianchi V, Borella S, Calderazzo F, et al. Inhibition of ribonucleotide reductase by 2ʹ-substituted deoxycytidine analogs: possible application in AIDS treatment. Proc Natl Acad Sci U S A. 1994 Aug 30;91(18):8403–8407.
- Burris HA 3rd, Moore MJ, Andersen J, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol. 1997 Jun;15(6):2403–2413. DOI:https://doi.org/10.1200/JCO.1997.15.6.2403.
- Amrutkar M, Gladhaug IP. Pancreatic cancer chemoresistance to Gemcitabine. Cancers (Basel). 2017 Nov 16;9(11):157.
- Uesaka K, Boku N, Fukutomi A, et al. Adjuvant chemotherapy of S-1 versus gemcitabine for resected pancreatic cancer: a phase 3, open-label, randomised, non-inferiority trial (JASPAC 01). Lancet. 2016 Jul 16;388(10041):248–257.
- Zeng S, Pottler M, Lan B, et al. Chemoresistance in Pancreatic Cancer. Int J Mol Sci. 2019 Sep 11;20(18):4504.
- Yang J, Ren B, Yang G, et al. The enhancement of glycolysis regulates pancreatic cancer metastasis. Cell Mol Life Sci. 2020 Jan;77(2):305–321. DOI:https://doi.org/10.1007/s00018-019-03278-z.
- Cao L, Wu J, Qu X, et al. Glycometabolic rearrangements–aerobic glycolysis in pancreatic cancer: causes, characteristics and clinical applications. J Exp Clin Cancer Res. 2020 Nov 30;39(1):267.
- Pascale RM, Calvisi DF, Simile MM, et al. The Warburg effect 97 Years after Its discovery. Cancers (Basel). 2020 Sep 30;12(10):2819.
- Lunt SY, Vander Heiden MG. Aerobic glycolysis: meeting the metabolic requirements of cell proliferation. Annu Rev Cell Dev Biol. 2011;27(1):441–464. DOI:https://doi.org/10.1146/annurev-cellbio-092910-154237.
- Vaupel P, Schmidberger H, Mayer A. The Warburg effect: essential part of metabolic reprogramming and central contributor to cancer progression. Int J Radiat Biol. 2019 Jul;95(7):912–919.
- Fan K, Fan ZY, Cheng H, et al. Hexokinase 2 dimerization and interaction with voltage-dependent anion channel promoted resistance to cell apoptosis induced by gemcitabine in pancreatic cancer. Cancer Med. 2019 Oct;8(13):5903–5915. DOI:https://doi.org/10.1002/cam4.2463.
- Timson DJ. Fructose 1,6-bisphosphatase: getting the message across. Biosci Rep. 2019 Mar 29;39(3):BSR20190124.
- Yan L, Raj P, Yao W, et al. Glucose metabolism in pancreatic cancer. Cancers (Basel). 2019 Sep 29;11(10):1460.
- Kato Y, Maeda T, Suzuki A, et al. Cancer metabolism: new insights into classic characteristics. Jpn Dent Sci Rev. 2018 Feb;54(1):8–21. DOI:https://doi.org/10.1016/j.jdsr.2017.08.003.
- Wang Z, Jiang Q, Dong C. Metabolic reprogramming in triple-negative breast cancer. Cancer Biol Med. 2020 Feb 15;17(1):44–59.
- Yuan LW, Yamashita H, Seto Y. Glucose metabolism in gastric cancer: the cutting-edge. World J Gastroenterol. 2016 Feb 14;22(6):2046–2059.
- Cardoso HJ, Carvalho TMA, Fonseca LRS, et al. Revisiting prostate cancer metabolism: from metabolites to disease and therapy. Med Res Rev. 2021 May;41(3):1499–1538. DOI:https://doi.org/10.1002/med.21766.
- Feinberg T, Herbig J, Kohl I, et al. Cancer metabolism: the volatile signature of glycolysis-in vitro model in lung cancer cells. J Breath Res. 2017 Jan 9;11(1):016008.
- Vernucci E, Abrego J, Gunda V, et al. Metabolic alterations in pancreatic cancer progression. Cancers (Basel). 2019 Dec 18;12(1):2.
- Ying H, Kimmelman AC, Lyssiotis CA, et al. Oncogenic Kras maintains pancreatic tumors through regulation of anabolic glucose metabolism. Cell. 2012 Apr 27;149(3):656–670. DOI:https://doi.org/10.1016/j.cell.2012.01.058.
- Zhang C, Liu J, Liang Y, et al., Tumour-associated mutant p53 drives the Warburg effect. Nat Commun. 4(1): 2935. 2013. DOI:https://doi.org/10.1038/ncomms3935. .
- Warburg O. On respiratory impairment in cancer cells. Science. 1956 Aug 10;124(3215):269–270.
- Warburg O. On the origin of cancer cells. Science. 1956 Feb 24;123(3191):309–314.
- Jia D, Park JH, Jung KH, et al. Elucidating the Metabolic Plasticity of Cancer: mitochondrial Reprogramming and Hybrid Metabolic States. Cells. 2018 Mar 13;7(3):21.
- Jones JB, Song JJ, Hempen PM, et al. Detection of mitochondrial DNA mutations in pancreatic cancer offers a “mass”-ive advantage over detection of nuclear DNA mutations. Cancer Res. 2001 Feb 15;61(4):1299–1304.
- Hardie RA, van Dam E, Cowley M, et al., Mitochondrial mutations and metabolic adaptation in pancreatic cancer. Cancer Metab. 5(1): 2. 2017. DOI:https://doi.org/10.1186/s40170-017-0164-1. .
- Jones S, Zhang X, Parsons DW, et al. Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science. 2008 Sep 26;321(5897):1801–1806.
- Kon N, Ou Y, Wang SJ, et al. mTOR inhibition acts as an unexpected checkpoint in p53-mediated tumor suppression. Genes Dev. 2021 Jan 1;35(1–2):59–64.
- Shen X, Chang LG, Hu MY, et al. KrasG12D-LOH promotes malignant biological behavior and energy metabolism of pancreatic ductal adenocarcinoma cells through the mTOR signaling pathway. Neoplasma. 2018;65(1):81–88. DOI:https://doi.org/10.4149/neo_2018_170224N142.
- He TL, Zhang YJ, Jiang H, et al. The c-Myc-LDHA axis positively regulates aerobic glycolysis and promotes tumor progression in pancreatic cancer. Med Oncol. 2015 Jul;32(7):187. DOI:https://doi.org/10.1007/s12032-015-0633-8.
- Dey P, Li J, Zhang J, et al. Oncogenic KRAS-driven metabolic reprogramming in pancreatic cancer cells Utilizes Cytokines from the tumor microenvironment. Cancer Discov. 2020 Apr;10(4):608–625. DOI:https://doi.org/10.1158/2159-8290.CD-19-0297.
- Blancher C, Moore JW, Robertson N, et al. Effects of ras and von Hippel-Lindau (VHL) gene mutations on hypoxia-inducible factor (HIF)-1alpha, HIF-2alpha, and vascular endothelial growth factor expression and their regulation by the phosphatidylinositol 3ʹ-kinase/Akt signaling pathway. Cancer Res. 2001 Oct 1;61(19):7349–7355.
- Chen C, Pore N, Behrooz A, et al. Regulation of glut1 mRNA by hypoxia-inducible factor-1. Interaction between H-ras and hypoxia. J Biol Chem. 2001 Mar 23;276(12):9519–9525.
- Halbrook CJ, Lyssiotis CA. Employing metabolism to improve the diagnosis and treatment of pancreatic cancer. Cancer Cell. 2017 Jan 9;31(1):5–19.
- Mello SS, Valente LJ, Raj N, et al. A p53 super-tumor suppressor reveals a tumor suppressive p53-Ptpn14-Yap Axis in Pancreatic Cancer. Cancer Cell. 2017 Oct 9;32(4):460–473 e6.
- Bensaad K, Tsuruta A, Selak MA, et al. TIGAR, a p53-inducible regulator of glycolysis and apoptosis. Cell. 2006 Jul 14;126(1):107–120.
- Sneeggen M, Guadagno NA, Progida C. Intracellular transport in cancer metabolic reprogramming. Front Cell Dev Biol. 2020;8:597608.
- Nagarajan A, Dogra SK, Sun L, et al. Paraoxonase 2 facilitates pancreatic cancer growth and metastasis by stimulating GLUT1-mediated glucose transport. Mol Cell. 2017 Aug 17;67(4):685–701 e6.
- Rai V, Agrawal S. Targets (Metabolic Mediators) of therapeutic importance in pancreatic ductal adenocarcinoma. Int J Mol Sci. 2020 Nov 12;21(22):8502.
- Butera G, Pacchiana R, Mullappilly N, et al. Mutant p53 prevents GAPDH nuclear translocation in pancreatic cancer cells favoring glycolysis and 2-deoxyglucose sensitivity. Biochim Biophys Acta Mol Cell Res. 2018 Dec;1865(12):1914–1923. DOI:https://doi.org/10.1016/j.bbamcr.2018.10.005.
- Barron CC, Bilan PJ, Tsakiridis T, et al. Facilitative glucose transporters: implications for cancer detection, prognosis and treatment. Metabolism. 2016 Feb;65(2):124–139. DOI:https://doi.org/10.1016/j.metabol.2015.10.007.
- Basturk O, Singh R, Kaygusuz E, et al. GLUT-1 expression in pancreatic neoplasia: implications in pathogenesis, diagnosis, and prognosis. Pancreas. 2011 Mar;40(2):187–192. DOI:https://doi.org/10.1097/MPA.0b013e318201c935.
- Kurahara H, Maemura K, Mataki Y, et al. Significance of Glucose Transporter Type 1 (GLUT-1) expression in the therapeutic strategy for pancreatic ductal adenocarcinoma. Ann Surg Oncol. 2018 May;25(5):1432–1439. DOI:https://doi.org/10.1245/s10434-018-6357-1.
- Amendola CR, Mahaffey JP, Parker SJ, et al. KRAS4A directly regulates hexokinase 1. Nature. 2019 Dec;576(7787):482–486. DOI:https://doi.org/10.1038/s41586-019-1832-9.
- Hirschey MD, DeBerardinis RJ, Diehl AME, et al. Dysregulated metabolism contributes to oncogenesis. Semin Cancer Biol. 2015 Dec;35(Suppl):S129–S150. DOI:https://doi.org/10.1016/j.semcancer.2015.10.002.
- Xu S, Herschman HR. A tumor agnostic therapeutic strategy for hexokinase 1-Null/hexokinase 2-positive cancers. Cancer Res. 2019 Dec 1;79(23):5907–5914.
- Kanai S, Shimada T, Narita T, et al. Phosphofructokinase-1 subunit composition and activity in the skeletal muscle, liver, and brain of dogs. J Vet Med Sci. 2019 May 31;81(5):712–716.
- Huangyang P, Li F, Lee P, et al. Fructose-1,6-bisphosphatase 2 inhibits sarcoma progression by restraining mitochondrial biogenesis. Cell Metab. 2020 Jan 7;31(1):174–188 e7.
- Han HS, Kang G, Kim JS, et al. Regulation of glucose metabolism from a liver-centric perspective. Exp Mol Med. 2016 Mar;11(48):e218. DOI:https://doi.org/10.1038/emm.2015.122.
- Yalcin A, Telang S, Clem B, et al. Regulation of glucose metabolism by 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatases in cancer. Exp Mol Pathol. 2009 Jun;86(3):174–179. DOI:https://doi.org/10.1016/j.yexmp.2009.01.003.
- Minchenko OH, Tsuchihara K, Minchenko DO, et al. Mechanisms of regulation of PFKFB expression in pancreatic and gastric cancer cells. World J Gastroenterol. 2014 Oct 14;20(38):13705–13717.
- Telang S, Clem BF, Klarer AC, et al. Small molecule inhibition of 6-phosphofructo-2-kinase suppresses t cell activation. J Transl Med. 2012 May 16;10(1):95.
- van Niekerk G, Engelbrecht AM. Role of PKM2 in directing the metabolic fate of glucose in cancer: a potential therapeutic target. Cell Oncol (Dordr). 2018 Aug;41(4):343–351.
- Li C, Zhao Z, Zhou Z, et al. PKM2 promotes cell survival and invasion under metabolic stress by enhancing Warburg effect in pancreatic ductal adenocarcinoma. Dig Dis Sci. 2016 Mar;61(3):767–773. DOI:https://doi.org/10.1007/s10620-015-3931-2.
- Azoitei N, Becher A, Steinestel K, et al. PKM2 promotes tumor angiogenesis by regulating HIF-1alpha through NF-kappaB activation. Mol Cancer. 2016 Jan 6;15(1):3.
- Feng J, Li J, Wu L, et al. Emerging roles and the regulation of aerobic glycolysis in hepatocellular carcinoma. J Exp Clin Cancer Res. 2020 Jul 6;39(1):126.
- Luo W, Hu H, Chang R, et al. Pyruvate kinase M2 is a PHD3-stimulated coactivator for hypoxia-inducible factor 1. Cell. 2011 May 27;145(5):732–744.
- Grandjean G, de Jong PR, James B, et al. Definition of a novel feed-forward mechanism for glycolysis-HIF1alpha signaling in hypoxic tumors highlights aldolase a as a therapeutic target. Cancer Res. 2016 Jul 15;76(14):4259–4269.
- Ji S, Zhang B, Liu J, et al. ALDOA functions as an oncogene in the highly metastatic pancreatic cancer. Cancer Lett. 2016 Apr 28;374(1):127–135.
- Hwang TL, Liang Y, Chien KY, et al. Overexpression and elevated serum levels of phosphoglycerate kinase 1 in pancreatic ductal adenocarcinoma. Proteomics. 2006 Apr;6(7):2259–2272. DOI:https://doi.org/10.1002/pmic.200500345.
- Liang C, Shi S, Qin Y, et al. Localisation of PGK1 determines metabolic phenotype to balance metastasis and proliferation in patients with SMAD4-negative pancreatic cancer. Gut. 2020;69(5):888–900. DOI:https://doi.org/10.1136/gutjnl-2018-317163.
- Cappello P, Tomaino B, Chiarle R, et al. An integrated humoral and cellular response is elicited in pancreatic cancer by alpha-enolase, a novel pancreatic ductal adenocarcinoma-associated antigen. Int J Cancer. 2009 Aug 1;125(3):639–648.
- Mohammad GH, Olde Damink SW, Malago M, et al. Pyruvate kinase M2 and Lactate Dehydrogenase A are overexpressed in pancreatic cancer and correlate with poor outcome. PLoS One. 2016;11(3):e0151635. DOI:https://doi.org/10.1371/journal.pone.0151635.
- Rong Y, Wu W, Ni X, et al. Lactate dehydrogenase A is overexpressed in pancreatic cancer and promotes the growth of pancreatic cancer cells. Tumour Biol. 2013 Jun;34(3):1523–1530. DOI:https://doi.org/10.1007/s13277-013-0679-1.
- Cui XG, Han ZT, He SH, et al. HIF1/2alpha mediates hypoxia-induced LDHA expression in human pancreatic cancer cells. Oncotarget. 2017 Apr 11;8(15):24840–24852.
- Sciacovelli M, Frezza C. Metabolic reprogramming and epithelial-to-mesenchymal transition in cancer. FEBS J. 2017 Oct;284(19):3132–3144.
- Locasale JW, Cantley LC. Altered metabolism in cancer. BMC Biol. 2010 Jun;25(8):88.
- Ito H, Duxbury M, Zinner MJ, et al. Glucose transporter-1 gene expression is associated with pancreatic cancer invasiveness and MMP-2 activity. Surgery. 2004 Sep;136(3):548–556. DOI:https://doi.org/10.1016/j.surg.2004.05.032.
- Capello M, Ferri-Borgogno S, Riganti C, et al. Targeting the Warburg effect in cancer cells through ENO1 knockdown rescues oxidative phosphorylation and induces growth arrest. Oncotarget. 2016 Feb 2;7(5):5598–5612.
- Zhao H, Duan Q, Zhang Z, et al. Up-regulation of glycolysis promotes the stemness and EMT phenotypes in gemcitabine-resistant pancreatic cancer cells. J Cell Mol Med. 2017 Sep;21(9):2055–2067. DOI:https://doi.org/10.1111/jcmm.13126.
- Xu Y, An X, Guo X, et al. Endothelial PFKFB3 plays a critical role in angiogenesis. Arterioscler Thromb Vasc Biol. 2014 Jun;34(6):1231–1239. DOI:https://doi.org/10.1161/ATVBAHA.113.303041.
- Gatenby RA, Gillies RJ. Why do cancers have high aerobic glycolysis? Nat Rev Cancer. 2004 Nov;4(11):891–899.
- Lardner A. The effects of extracellular pH on immune function. J Leukoc Biol. 2001 Apr;69(4):522–530.
- Husain Z, Huang Y, Seth P, et al. Tumor-derived lactate modifies antitumor immune response: effect on myeloid-derived suppressor cells and NK cells. J Immunol. 2013 Aug 1;191(3):1486–1495.
- Patel S, Fu S, Mastio J, et al. Unique pattern of neutrophil migration and function during tumor progression. Nat Immunol. 2018 Nov;19(11):1236–1247. DOI:https://doi.org/10.1038/s41590-018-0229-5.
- Penny HL, Sieow JL, Adriani G, et al. Warburg metabolism in tumor-conditioned macrophages promotes metastasis in human pancreatic ductal adenocarcinoma. Oncoimmunology. 2016 Aug;5(8):e1191731. DOI:https://doi.org/10.1080/2162402X.2016.1191731.
- Lin J, Xia L, Liang J, et al. The roles of glucose metabolic reprogramming in chemo- and radio-resistance. J Exp Clin Cancer Res. 2019 May 23;38(1):218. DOI:https://doi.org/10.1186/s13046-019-1214-z.
- Intensity Modulated Radiation Therapy Collaborative Working G. Intensity-modulated radiotherapy: current status and issues of interest. Int J Radiat Oncol Biol Phys. 2001 Nov 15;51(4): 880–914. DOI:https://doi.org/10.1016/S0360-3016(01)01749-7.
- Wagner W, Ciszewski WM, Kania KDL. D-lactate enhance DNA repair and modulate the resistance of cervical carcinoma cells to anticancer drugs via histone deacetylase inhibition and hydroxycarboxylic acid receptor 1 activation. Cell Commun Signal. 2015 Jul 25;13(1):36.
- Xu W, Wang S, Chen Q, et al. TXNL1-XRCC1 pathway regulates cisplatin-induced cell death and contributes to resistance in human gastric cancer. Cell Death Dis. 2014 Feb 13;5(2):e1055.
- Dai S, Peng Y, Zhu Y, et al. Glycolysis promotes the progression of pancreatic cancer and reduces cancer cell sensitivity to gemcitabine. Biomed Pharmacother. 2020 Jan;121:109521.
- Fan K, Fan Z, Cheng H, et al. Hexokinase 2 dimerization and interaction with voltage-dependent anion channel promoted resistance to cell apoptosis induced by gemcitabine in pancreatic cancer. Cancer Med. 2019 Oct;8(13):5903–5915.
- Jin X, Pan Y, Wang L, et al. Fructose-1,6-bisphosphatase Inhibits ERK activation and bypasses gemcitabine resistance in pancreatic cancer by blocking IQGAP1-MAPK Interaction. Cancer Res. 2017 Aug 15;77(16):4328–4341.
- Mehla K, Singh PK. MUC1: a novel metabolic master regulator. Biochim Biophys Acta. 2014 Apr;1845(2):126–135.
- Gunda V, Souchek J, Abrego J, et al. MUC1-mediated metabolic alterations regulate response to radiotherapy in pancreatic cancer. Clin Cancer Res. 2017 Oct 1;23(19):5881–5891.
- Hudson CD, Hagemann T, Mather SJ, et al. Resistance to the tyrosine kinase inhibitor axitinib is associated with increased glucose metabolism in pancreatic adenocarcinoma. Cell Death Dis. 2014 Apr;10(5):e1160. DOI:https://doi.org/10.1038/cddis.2014.125.
- Dang CV, O’Donnell KA, Zeller KI, et al. The c-Myc target gene network. Semin Cancer Biol. 2006 Aug;16(4):253–264. DOI:https://doi.org/10.1016/j.semcancer.2006.07.014.
- Rajbhandari N, Lin WC, Wehde BL, et al. Autocrine IGF1 signaling mediates pancreatic tumor cell dormancy in the absence of oncogenic drivers. Cell Rep. 2017 Feb 28;18(9):2243–2255.
- Dang CV, Le A, Gao P. MYC-induced cancer cell energy metabolism and therapeutic opportunities. Clin Cancer Res. 2009 Nov 1;15(21):6479–6483.
- Ji L, Wei Y, Jiang T, et al. Correlation of Nrf2, NQO1, MRP1, cmyc and p53 in colorectal cancer and their relationships to clinicopathologic features and survival. Int J Clin Exp Pathol. 2014;7(3):1124–1131.
- Hessmann E, Schneider G, Ellenrieder V, et al. MYC in pancreatic cancer: novel mechanistic insights and their translation into therapeutic strategies. Oncogene. 2016 Mar 31;35(13):1609–1618. DOI:https://doi.org/10.1038/onc.2015.216.
- Hsieh AL, Walton ZE, Altman BJ, et al. MYC and metabolism on the path to cancer. Semin Cell Dev Biol. 2015 Jul;43:11–21.
- Zhang X, Xu J, Yan R, et al. FAM84B, amplified in pancreatic ductal adenocarcinoma, promotes tumorigenesis through the Wnt/beta-catenin pathway. Aging (Albany NY). 2020 Apr 14;12(8):6808–6822.
- Jiang Y, Lin X, Kapoor A, et al. FAM84B promotes prostate tumorigenesis through a network alteration. Ther Adv Med Oncol. 2019;11:1758835919846372.
- Hua YQ, Zhang K, Sheng J, et al. Fam83D promotes tumorigenesis and gemcitabine resistance of pancreatic adenocarcinoma through the Wnt/beta-catenin pathway. Life Sci. 2021 Feb;8:119205.
- Ram Makena M, Gatla H, Verlekar D, et al. Wnt/beta-catenin signaling: the culprit in pancreatic carcinogenesis and therapeutic resistance. Int J Mol Sci. 2019 Aug 30;20(17):4242.
- Tong Y, Guo D, Yan D, et al. KAT2A succinyltransferase activity-mediated 14-3-3zeta upregulation promotes beta-catenin stabilization-dependent glycolysis and proliferation of pancreatic carcinoma cells. Cancer Lett. 2020 Jan 28;469:1–10. DOI:https://doi.org/10.1016/j.canlet.2019.09.015.
- Inuzuka H, Shaik S, Onoyama I, et al. SCF(FBW7) regulates cellular apoptosis by targeting MCL1 for ubiquitylation and destruction. Nature. 2011 Mar 3;471(7336):104–109.
- Qin Y, Hu Q, Xu J, et al. PRMT5 enhances tumorigenicity and glycolysis in pancreatic cancer via the FBW7/cMyc axis. Cell Commun Signal. 2019 Mar 29;17(1):30.
- Ji S, Qin Y, Shi S, et al. ERK kinase phosphorylates and destabilizes the tumor suppressor FBW7 in pancreatic cancer. Cell Res. 2015 May;25(5):561–573. DOI:https://doi.org/10.1038/cr.2015.30.
- Shang Y, Zhang J, Huang EJ. HIPK2-mediated transcriptional control of NMDA receptor subunit expression regulates neuronal survival and cell death. J Neurosci. 2018 Apr 18;38(16):4006–4019.
- Qin Y, Hu Q, Ji S, et al. Homeodomain-interacting protein kinase 2 suppresses proliferation and aerobic glycolysis via ERK/cMyc axis in pancreatic cancer. Cell Prolif. 2019 May;52(3):e12603. DOI:https://doi.org/10.1111/cpr.12603.
- Chai F, Liang Y, Bi J, et al. REGgamma regulates ERalpha degradation via ubiquitin-proteasome pathway in breast cancer. Biochem Biophys Res Commun. 2015 Jan 2;456(1):534–540.
- Guo J, Hao J, Jiang H, et al. Proteasome activator subunit 3 promotes pancreatic cancer growth via c-Myc-glycolysis signaling axis. Cancer Lett. 2017 Feb 1;386:161–167. DOI:https://doi.org/10.1016/j.canlet.2016.08.018.
- Jin X, Fang R, Fan P, et al. PES1 promotes BET inhibitors resistance and cells proliferation through increasing c-Myc expression in pancreatic cancer. J Exp Clin Cancer Res. 2019 Nov 12;38(1):463.
- Xi Y, Yuan P, Li T, et al. hENT1 reverses chemoresistance by regulating glycolysis in pancreatic cancer. Cancer Lett. 2020 Jun 1;479:112–122. DOI:https://doi.org/10.1016/j.canlet.2020.03.015.
- Alsafadi S, Houy A, Battistella A, et al. Cancer-associated SF3B1 mutations affect alternative splicing by promoting alternative branchpoint usage. Nat Commun. 2016 Feb 4;7(1):10615.
- Kesarwani AK, Ramirez O, Gupta AK, et al. Cancer-associated SF3B1 mutants recognize otherwise inaccessible cryptic 3ʹ splice sites within RNA secondary structures. Oncogene. 2017 Feb 23;36(8):1123–1133.
- Yang JY, Huo YM, Yang MW, et al. SF3B1 mutation in pancreatic cancer contributes to aerobic glycolysis and tumor growth through a PP2A-c-Myc axis. Mol Oncol. 2021 May 1;15(11):3076–3090.
- Denko NC. Hypoxia, HIF1 and glucose metabolism in the solid tumour. Nat Rev Cancer. 2008 Sep;8(9):705–713.
- Liu Z, Jia X, Duan Y, et al. Excess glucose induces hypoxia-inducible factor-1alpha in pancreatic cancer cells and stimulates glucose metabolism and cell migration. Cancer Biol Ther. 2013 May;14(5):428–435. DOI:https://doi.org/10.4161/cbt.23786.
- Jiang Y, Wu GH, He GD, et al. The effect of silencing HIF-1alpha Gene in BxPC-3 cell line on glycolysis-related gene expression, cell growth, invasion, and apoptosis. Nutr Cancer. 2015;67(8):1314–1323. DOI:https://doi.org/10.1080/01635581.2015.1085584.
- Zhong H, De Marzo AM, Laughner E, et al. Overexpression of hypoxia-inducible factor 1alpha in common human cancers and their metastases. Cancer Res. 1999 Nov 15;59(22):5830–5835.
- He G, Jiang Y, Zhang B, et al. The effect of HIF-1alpha on glucose metabolism, growth and apoptosis of pancreatic cancerous cells. Asia Pac J Clin Nutr. 2014;23(1):174–180. DOI:https://doi.org/10.6133/apjcn.2014.23.1.14.
- Wassing IE, Esashi F. RAD51: beyond the break. Semin Cell Dev Biol. 2021 May;113:38–46.
- Zhang X, Ma N, Yao W, et al. RAD51 is a potential marker for prognosis and regulates cell proliferation in pancreatic cancer. Cancer Cell Int. 2019;19(1):356. DOI:https://doi.org/10.1186/s12935-019-1077-6.
- Park KC, Paluncic J, Kovacevic Z, et al. Pharmacological targeting and the diverse functions of the metastasis suppressor, NDRG1, in cancer. Free Radic Biol Med. 2020 Sep;157:154–175.
- Liu W, Zhang B, Hu Q, et al. A new facet of NDRG1 in pancreatic ductal adenocarcinoma: suppression of glycolytic metabolism. Int J Oncol. 2017 May;50(5):1792–1800. DOI:https://doi.org/10.3892/ijo.2017.3938.
- Wang G, Li Y, Yang Z, et al. ROS mediated EGFR/MEK/ERK/HIF-1alpha Loop Regulates Glucose metabolism in pancreatic cancer. Biochem Biophys Res Commun. 2018 Jun 12;500(4):873–878.
- Hu LP, Zhang XX, Jiang SH, et al. Targeting purinergic receptor P2Y2 prevents the growth of pancreatic ductal adenocarcinoma by inhibiting cancer cell glycolysis. Clin Cancer Res. 2019 Feb 15;25(4):1318–1330.
- Bianchi ME, Agresti A. HMG proteins: dynamic players in gene regulation and differentiation. Curr Opin Genet Dev. 2005 Oct;15(5):496–506.
- Cai X, Ding HJ, Liu YX, et al. Expression of HMGB2 indicates worse survival of patients and is required for the maintenance of Warburg effect in pancreatic cancer. Acta Biochim Biophys Sin (Shanghai). 2017 Feb;49(2):119–127. DOI:https://doi.org/10.1093/abbs/gmw124.
- Zhang ZB, Liu N. Long non-coding RNA KTN1-AS1 promotes progression in pancreatic cancer through regulating microRNA-23b-3p/high-mobility group box 2 axis. Aging (Albany NY). 2021 Aug 30;13(16):20820–20835.
- Zhao M, Mishra L, Deng CX. The role of TGF-beta/SMAD4 signaling in cancer. Int J Biol Sci. 2018;14(2):111–123.
- Costanza B, Rademaker G, Tiamiou A, et al. Transforming growth factor beta-induced, an extracellular matrix interacting protein, enhances glycolysis and promotes pancreatic cancer cell migration. Int J Cancer. 2019;145(6):1570–1584. DOI:https://doi.org/10.1002/ijc.32247.
- Yan B, Jiang ZD, Cheng L, et al. Paracrine HGF/c-MET enhances the stem cell-like potential and glycolysis of pancreatic cancer cells via activation of YAP/HIF-1 alpha. Exp Cell Res. 2018 Oct;371(1):63–71. DOI:https://doi.org/10.1016/j.yexcr.2018.07.041.
- Xu Z, Pang TCY, Liu AC, et al. Targeting the HGF/c-MET pathway in advanced pancreatic cancer: a key element of treatment that limits primary tumour growth and eliminates metastasis. Br J Cancer. 2020 May;122(10):1486–1495. DOI:https://doi.org/10.1038/s41416-020-0782-1.
- Shi S, Xu J, Zhang B, et al. VEGF promotes glycolysis in pancreatic cancer via HIF1 alpha up-regulation. Curr Mol Med. 2016;16(4):394–403. DOI:https://doi.org/10.2174/1566524016666160316153623.
- Chaika NV, Gebregiworgis T, Lewallen ME, et al. MUC1 mucin stabilizes and activates hypoxia-inducible factor 1 alpha to regulate metabolism in pancreatic cancer. Proc Natl Acad Sci U S A. 2012 Aug 21;109(34):13787–13792.
- Vogt DL, Gray CD, Young WS 3rd, et al. ARHGAP4 is a novel RhoGAP that mediates inhibition of cell motility and axon outgrowth. Mol Cell Neurosci. 2007 Nov;36(3):332–342. DOI:https://doi.org/10.1016/j.mcn.2007.07.004.
- Shen YH, Chen G, Zhuang LP, et al. ARHGAP4 mediates the Warburg effect in pancreatic cancer through the mTOR and HIF-1 alpha signaling pathways. Onco Targets Ther. 2019;12:5003–5012.
- Chang HC, Guarente L. SIRT1 and other sirtuins in metabolism. Trends Endocrinol Metab. 2014 Mar;25(3):138–145.
- Alves-Fernandes DK, Jasiulionis MG. The role of SIRT1 on DNA damage response and epigenetic alterations in cancer. Int J Mol Sci. 2019 Jun 28;20(13):3153.
- Hu Q, Qin Y, Ji S, et al. UHRF1 promotes aerobic glycolysis and proliferation via suppression of SIRT4 in pancreatic cancer. Cancer Lett. 2019 Jun 28;452:226–236. DOI:https://doi.org/10.1016/j.canlet.2019.03.024.
- Haigis MC, Deng CX, Finley LW, et al. SIRT3 is a mitochondrial tumor suppressor: a scientific tale that connects aberrant cellular ROS, the Warburg effect, and carcinogenesis. Cancer Res. 2012 May 15;72(10):2468–2472.
- Yao WT, Ji SR, Qin Y, et al. Profilin-1 suppresses tumorigenicity in pancreatic cancer through regulation of the SIRT3-HIF1 alpha axis. Mol Cancer. 2014 Aug;13(1). DOI:https://doi.org/10.1186/1476-4598-13-187.
- Gorres KL, Raines RT. Prolyl 4-hydroxylase. Crit Rev Biochem Mol Biol. 2010 Apr;45(2):106–124.
- Cao XP, Cao Y, Li WJ, et al. P4HA1/HIF1 alpha feedback loop drives the glycolytic and malignant phenotypes of pancreatic cancer. Biochem Biophys Res Commun. 2019 Aug;516(3):606–612. DOI:https://doi.org/10.1016/j.bbrc.2019.06.096.
- Qin Y, Zhu WW, Xu WY, et al. LSD1 sustains pancreatic cancer growth via maintaining HIF1 alpha-dependent glycolytic process. Cancer Lett. 2014 Jun;347(2):225–232. DOI:https://doi.org/10.1016/j.canlet.2014.02.013.
- Xiang JF, Hu QS, Qin Y, et al. TCF7L2 positively regulates aerobic glycolysis via the EGLN2/HIF-1 alpha axis and indicates prognosis in pancreatic cancer. Cell Death Dis. 2018 Feb;9(3). DOI:https://doi.org/10.1038/s41419-018-0367-6.
- Werle SD, Schwab JD, Tatura M, et al. Unraveling the molecular tumor-promoting regulation of Cofilin-1 in pancreatic cancer. Cancers (Basel). 2021 Feb 10;13(4):725.
- Baretic D, Williams RL. The structural basis for mTOR function. Semin Cell Dev Biol. 2014 Dec;36:91–101.
- Duvel K, Yecies JL, Menon S, et al. Activation of a metabolic gene regulatory network downstream of mTOR complex 1. Mol Cell. 2010 Jul 30;39(2):171–183.
- Maiese K, Chong ZZ, Shang YC, et al. mTOR: on target for novel therapeutic strategies in the nervous system. Trends Mol Med. 2013 Jan;19(1):51–60. DOI:https://doi.org/10.1016/j.molmed.2012.11.001.
- Cybulski N, Hall MN. TOR complex 2: a signaling pathway of its own. Trends Biochem Sci. 2009 Dec;34(12):620–627.
- Sarbassov DD, Guertin DA, Ali SM, et al. Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science. 2005 Feb 18;307(5712):1098–1101.
- Ikenoue T, Inoki K, Yang Q, et al. Essential function of TORC2 in PKC and Akt turn motif phosphorylation, maturation and signalling. EMBO J. 2008 Jul 23;27(14):1919–1931.
- Ebrahimi S, Hosseini M, Shahidsales S, et al. Targeting the Akt/PI3K signaling pathway as a potential therapeutic strategy for the treatment of pancreatic cancer. Curr Med Chem. 2017;24(13):1321–1331. DOI:https://doi.org/10.2174/0929867324666170206142658.
- Aoki M, Fujishita T. Oncogenic Roles of the PI3K/AKT/mTOR Axis. Curr Top Microbiol Immunol. 2017;407:153–189.
- Duan JJ, Cai J, Guo YF, et al. ALDH1A3, a metabolic target for cancer diagnosis and therapy. Int J Cancer. 2016 Sep 1;139(5):965–975.
- Nie S, Qian XT, Shi MY, et al. ALDH1A3 Accelerates Pancreatic Cancer Metastasis by Promoting Glucose Metabolism. Front Oncol. 2020 Jun;10. DOI:https://doi.org/10.3389/fonc.2020.00915
- Reymond A, Meroni G, Fantozzi A, et al. The tripartite motif family identifies cell compartments. EMBO J. 2001 May 1;20(9):2140–2151.
- Li RK, Weng L, Liu BY, et al. TRIM59 predicts poor prognosis and promotes pancreatic cancer progression via the PI3K/AKT/mTOR-glycolysis signaling axis. J Cell Biochem. 2020 Feb;121(2):1986–1997. DOI:https://doi.org/10.1002/jcb.29433.
- Jiang SH, Li J, Dong FY, et al. Increased serotonin signaling contributes to the Warburg effect in pancreatic tumor cells under metabolic stress and promotes growth of pancreatic tumors in mice. Gastroenterology. 2017 Jul;153(1):277–291.e19. DOI:https://doi.org/10.1053/j.gastro.2017.03.008.
- Hu MY, Chen XX, Ma L, et al. AMPK inhibition suppresses the malignant phenotype of pancreatic cancer cells in part by attenuating aerobic Glycolysis. J Cancer. 2019;10(8):1870–1878. DOI:https://doi.org/10.7150/jca.28299.
- Ni FB, Tang HJ, Wang C, et al. Baohuoside I inhibits the proliferation of pancreatic cancer cells via mTOR/S6K1-Caspases/Bcl2/Bax Apoptotic Signaling. Cancer Manag Res. 2019;11:10609–10621.
- Pelletier J, Roux D, Viollet B, et al. AMP-activated protein kinase is dispensable for maintaining ATP levels and for survival following inhibition of glycolysis, but promotes tumour engraftment of Ras-transformed fibroblasts. Oncotarget. 2015 May 20;6(14):11833–11847.
- Liang J, Mills GB. AMPK: a contextual oncogene or tumor suppressor? Cancer Res. 2013May15;73(10):2929–2935.DOI:https://doi.org/10.1158/0008-5472.CAN-12-3876.
- Faubert B, Vincent EE, Poffenberger MC, et al. The AMP-activated protein kinase (AMPK) and cancer: many faces of a metabolic regulator. Cancer Lett. 2015 Jan 28;356(2Pt A):165–170.
- Bonini MG, Gantner BN. The multifaceted activities of AMPK in tumor progression–why the “one size fits all” definition does not fit at all? IUBMB Life. 2013 Nov;65(11):889–896.
- Feng MY, Xiong GB, Cao Z, et al. LAT2 regulates glutamine-dependent mTOR activation to promote glycolysis and chemoresistance in pancreatic cancer. J Exp Clin Cancer Res. 2018 Nov;37(1). DOI:https://doi.org/10.1186/s13046-018-0947-4.
- Totiger TM, Srinivasan S, Jala VR, et al. Urolithin A, a novel natural compound to target PI3K/AKT/mTOR pathway in pancreatic cancer. Mol Cancer Ther. 2019 Feb;18(2):301–311. DOI:https://doi.org/10.1158/1535-7163.MCT-18-0464.
- Shankaraiah RC, Veronese A, Sabbioni S, et al. Non-coding RNAs in the reprogramming of glucose metabolism in cancer. Cancer Lett. 2018 Apr;10(419):167–174. DOI:https://doi.org/10.1016/j.canlet.2018.01.048.
- Xia M, Feng S, Chen Z, et al. Non-coding RNAs: key regulators of aerobic glycolysis in breast cancer. Life Sci. 2020 Jun;1(250):117579. DOI:https://doi.org/10.1016/j.lfs.2020.117579.
- Bartel DP. MicroRNAs: target recognition and regulatory functions. Cell. 2009 Jan 23;136(2):215–233.
- Xu Z, Zhang D, Zhang Z, et al. MicroRNA-505, suppressed by oncogenic long non-coding RNA LINC01448, acts as a novel suppressor of glycolysis and tumor progression through inhibiting HK2 expression in pancreatic cancer. Front Cell Dev Biol. 2021 Jan;15;8(18):1725–1727. DOI:https://doi.org/10.1016/0006-2952(75)90013-1.
- Wang S-J, Li X-D, Wu L-P, et al. MicroRNA-202 suppresses glycolysis of pancreatic cancer by targeting hexokinase 2. J Cancer. 2021;12(4):1144–1153. DOI:https://doi.org/10.7150/jca.43379.
- Yang Y, Gabra MBI, Hanse EA, et al. MiR-135 suppresses glycolysis and promotes pancreatic cancer cell adaptation to metabolic stress by targeting phosphofructokinase-1. Nat Commun. 2019Feb;10(1):809.
- Gu DN, Jiang MJ, Mei Z, et al. microRNA-7 impairs autophagy-derived pools of glucose to suppress pancreatic cancer progression. Cancer Lett. 2017;400:69–78.
- Ye ZQ, Zou CL, Chen HB, et al. MicroRNA-7 as a potential biomarker for prognosis in pancreatic cancer. Dis Markers. 2020;2020:1–13.
- Tu MJ, Duan ZJ, Liu ZZ, et al. MicroRNA-1291-5p sensitizes pancreatic carcinoma cells to arginine deprivation and chemotherapy through the regulation of arginolysis and glycolysis. Mol Pharmacol. 2020 Dec;98(6):686–694. DOI:https://doi.org/10.1124/molpharm.120.000130.
- Liu L, Gong LS, Zhang YD, et al. Glycolysis in Panc-1 human pancreatic cancer cells is inhibited by everolimus. Exp Ther Med. 2013 Jan;5(1):338–342. DOI:https://doi.org/10.3892/etm.2012.787.
- Ma ML, Ma CF, Li PP, et al. Low glucose enhanced metformin’s inhibitory effect on pancreatic cancer cells by suppressing glycolysis and inducing energy stress via up-regulation of miR-210-5p. Cell Cycle. 2020 Sep;19(17):2168–2181. DOI:https://doi.org/10.1080/15384101.2020.1796036.
- Wu DH, Liang H, Lu SN, et al. miR-124 suppresses pancreatic ductal adenocarcinoma growth by regulating monocarboxylate transporter 1-mediated cancer lactate metabolism. Cell Physiol Biochem. 2018;50(3):924–935. DOI:https://doi.org/10.1159/000494477.
- Zhai SY, Xu ZW, Xie JJ, et al. Epigenetic silencing of LncRNA LINC00261 promotes c-myc-mediated aerobic glycolysis by regulating miR-222-3p/HIPK2/ERK axis and sequestering IGF2BP1. Oncogene. 2021;40(2):277–291.
- Rafiee A, Riazi-Rad F, Havaskary M, et al. Long noncoding RNAs: regulation, function and cancer. Biotechnol Genet Eng Rev. 2018 Oct;34(2):153–180. DOI:https://doi.org/10.1080/02648725.2018.1471566.
- Zhou X, Gao W, Hua HH, et al. LncRNA-BLACAT1 facilitates proliferation, migration and aerobic glycolysis of pancreatic cancer cells by repressing CDKN1C via EZH2-Induced H3K27me3. Front Oncol. 2020 Sep;10. DOI:https://doi.org/10.3389/fonc.2020.539805
- Sun JW, Zhang PP, Tao Y, et al. Upregulation of LncRNA PVT1 facilitates pancreatic ductal adenocarcinoma cell progression and glycolysis by regulating MiR-519d-3p and HIF-1A. J Cancer. 2020;11(9):2572–2579. DOI:https://doi.org/10.7150/jca.37959.
- Zhang Z, Fang E, Rong Y, et al. Hypoxia-induced lncRNA CASC9 enhances glycolysis and the epithelial-mesenchymal transition of pancreatic cancer by a positive feedback loop with AKT/HIF-1alpha signaling. Am J Cancer Res. 2021;11(1):123–137.
- Xu M, Cui R, Ye L, et al. LINC00941 promotes glycolysis in pancreatic cancer by modulating the Hippo pathway. Mol Ther Nucleic Acids. 2021 Dec 3;26:280–294. DOI:https://doi.org/10.1016/j.omtn.2021.07.004.
- Wan Z, Jiang H, Li L, et al. Carcinogenic roles and therapeutic effects of EZH2 in gynecological cancers. Bioorg Med Chem. 2020 Apr 1;28(7):115379.
- Zhu W, Zhang W, Xu N, et al. Dihydroartemisinin induces apoptosis and downregulates glucose metabolism in JF-305 pancreatic cancer cells. RSC Adv. 2018;8(37):20692–20700. DOI:https://doi.org/10.1039/C8RA00565F.
- Melstrom LG, Salabat MR, Ding XZ, et al. Apigenin inhibits the GLUT-1 glucose transporter and the phosphoinositide 3-kinase/Akt pathway in human pancreatic cancer cells. Pancreas. 2008 Nov;37(4):426–431. DOI:https://doi.org/10.1097/MPA.0b013e3181735ccb.
- Kawatani M, Aono H, Hiranuma S, et al. Identification of a small-molecule glucose transporter inhibitor, glutipyran, that inhibits cancer cell growth. ACS Chem Biol. 2021;16(8):1576–1586. DOI:https://doi.org/10.1021/acschembio.1c00480.
- Chapiro J, Sur S, Savic LJ, et al. Systemic delivery of microencapsulated 3-bromopyruvate for the therapy of pancreatic cancer. Clin Cancer Res. 2014 Dec 15;20(24):6406–6417.
- Pajak B, Siwiak E, Soltyka M, et al. 2-Deoxy-d-Glucose and its analogs: from diagnostic to therapeutic agents. Int J Mol Sci. 2019 Dec 29;21(1):234.
- Jiang SH, Dong FY, Da LT, et al. Ikarugamycin inhibits pancreatic cancer cell glycolysis by targeting hexokinase 2. FASEB J. 2020 Mar;34(3):3943–3955. DOI:https://doi.org/10.1096/fj.201901237R.
- Redman RA, Pohlmann PR, Kurman MR, et al. A phase I, dose-escalation, multicenter study of ACT-PFK-158, 2HCl in patients with advanced solid malignancies explores a first-in-human inhibitor of glycolysis. J clin oncol. 2015 Jan;33(3):TPS494.
- Gustafsson NMS, Farnegardh K, Bonagas N, et al. Targeting PFKFB3 radiosensitizes cancer cells and suppresses homologous recombination. Nat Commun. 2018 Sep 24;9(1):3872.
- Mohammad GH, Vassileva V, Acedo P, et al. Targeting pyruvate kinase m2 and lactate dehydrogenase a is an effective combination strategy for the treatment of pancreatic cancer. Cancers (Basel). 2019;11(9):1372. DOI:https://doi.org/10.3390/cancers11091372.
- James AD, Richardson DA, Oh IW, et al. Cutting off the fuel supply to calcium pumps in pancreatic cancer cells: role of pyruvate kinase-M2 (PKM2). Br J Cancer. 2020 Jan;122(2):266–278. DOI:https://doi.org/10.1038/s41416-019-0675-3.
- Maftouh M, Avan A, Sciarrillo R, et al. Synergistic interaction of novel lactate dehydrogenase inhibitors with gemcitabine against pancreatic cancer cells in hypoxia. Br J Cancer. 2014 Jan 7;110(1):172–182.
- Granchi C, Roy S, De Simone A, et al. N-Hydroxyindole-based inhibitors of lactate dehydrogenase against cancer cell proliferation. Eur J Med Chem. 2011;46(11):5398–5407. DOI:https://doi.org/10.1016/j.ejmech.2011.08.046.
- Rajeshkumar NV, Dutta P, Yabuuchi S, et al. Therapeutic targeting of the Warburg effect in Pancreatic Cancer relies on an absence of p53 function. Cancer Res. 2015 Aug 15;75(16):3355–3364.
- Miyake K, Nishioka M, Imura S, et al. The novel hypoxic cytotoxin, TX-2098 has antitumor effect in pancreatic cancer; possible mechanism through inhibiting VEGF and hypoxia inducible factor-1alpha targeted gene expression. Exp Cell Res. 2012 Aug 1;318(13):1554–1563.
- Liberti MV, Dai Z, Wardell SE, et al. A Predictive Model for Selective Targeting of the Warburg Effect through GAPDH Inhibition with a Natural Product. Cell Metab. 2017 Oct 3;26(4):648–659 e8.
- Canon J, Rex K, Saiki AY, et al. The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity. Nature. 2019 Nov;575(7781):217–223. DOI:https://doi.org/10.1038/s41586-019-1694-1.
- Duffy MJ, O’Grady S, Tang M, et al. MYC as a target for cancer treatment. Cancer Treat Rev. 2021 Mar;94:102154.
- Blackwell TK, Huang J, Ma A, et al. Binding of myc proteins to canonical and noncanonical DNA sequences. Mol Cell Biol. 1993 Sep;13(9):5216–5224. DOI:https://doi.org/10.1128/mcb.13.9.5216-5224.1993.
- Masso-Valles D, Soucek L. Blocking Myc to treat cancer: reflecting on two decades of omomyc. Cells. 2020Apr4;9(4):883.DOI:https://doi.org/10.3390/cells9040883.
- Shukla SK, Dasgupta A, Mehla K, et al. Silibinin-mediated metabolic reprogramming attenuates pancreatic cancer-induced cachexia and tumor growth. Oncotarget. 2015 Dec 1;6(38):41146–41161.
- Zhang M, Fan HY, Li SC. Inhibition of c-Myc by 10058-F4 induces growth arrest and chemosensitivity in pancreatic ductal adenocarcinoma. Biomed Pharmacother. 2015;73:123–128.
- Greenberger LM, Horak ID, Filpula D, et al. A RNA antagonist of hypoxia-inducible factor-1alpha, EZN-2968, inhibits tumor cell growth. Mol Cancer Ther. 2008 Nov;7(11):3598–3608. DOI:https://doi.org/10.1158/1535-7163.MCT-08-0510.
- Jeong W, Rapisarda A, Park SR, et al. Pilot trial of EZN-2968, an antisense oligonucleotide inhibitor of hypoxia-inducible factor-1 alpha (HIF-1alpha), in patients with refractory solid tumors. Cancer Chemother Pharmacol. 2014 Feb;73(2):343–348. DOI:https://doi.org/10.1007/s00280-013-2362-z.
- Wigerup C, Pahlman S, Bexell D. Therapeutic targeting of hypoxia and hypoxia-inducible factors in cancer. Pharmacol Ther. 2016 Aug;164:152–169.
- Ong SB, Katwadi K, Kwek XY, et al. Non-coding RNAs as therapeutic targets for preventing myocardial ischemia-reperfusion injury. Expert Opin Ther Targets. 2018 Mar;22(3):247–261. DOI:https://doi.org/10.1080/14728222.2018.1439015.
- Roovers J, De Jonghe P, Weckhuysen S. The therapeutic potential of RNA regulation in neurological disorders. Expert Opin Ther Targets. 2018 Dec;22(12):1017–1028.
- Wang S, Li MY, Liu Y, et al. The role of microRNA in cisplatin resistance or sensitivity. Expert Opin Ther Targets. 2020 Sep;24(9):885–897. DOI:https://doi.org/10.1080/14728222.2020.1785431.